Latigo’s team is celebrating ringing the Nasdaq opening bell on the day it debuted. (courtesy photo) The Central Coast had gone years without a traditional initial public offering, but that streak broke when Thousand Oaks-based Latigo Biotherapuetics boosted the biotech scene of the Conejo Valley with a better-than-expected raise. Latigo, which specializes in developing non-opioid…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
